RLMD
$6.07-0.18 (-2.88%)
Relmada Therapeutics, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clin...
Recent News
Relmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Highlights: Strategic Advancements and ...
Relmada Therapeutics Inc (RLMD) reports significant progress in clinical trials and financial strategies, despite increased net loss and administrative expenses.
Relmada Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Relmada Therapeutics, Inc.'s Q4 2025 earnings call
Relmada (RLMD) Q4 2025 Earnings Call Transcript
With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a summary of recent business highlights; Dr. Raj S. Pruthi, Relmada Therapeutics, Inc.'s CMO, Oncology, who will provide an NDV01 program update; and Relmada Therapeutics, Inc.'s CFO, Maged S. Shenouda, who will provide an update on sopranolone and a review of the company's Q4 financial results. Now, I would like to hand the call over to Sergio Traversa. Sergio Traversa: Thank you, Brian.
Relmada Therapeutics Q4 Earnings Call Highlights
Relmada Therapeutics (NASDAQ:RLMD) outlined progress on its lead urology oncology program and reviewed fourth-quarter results during its fourth quarter and full year 2025 earnings call, highlighting durable Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC), plans to begin a Phase
Why Relmada Therapeutics (RLMD) Is Up 38.8% After $160M Raise And Positive NDV-01 Phase 2 Data
Relmada Therapeutics recently reported past 12‑month interim Phase 2 data for NDV-01 in high-risk non-muscle invasive bladder cancer, showing strong complete response rates and a favorable safety profile, and has secured an oversubscribed US$160,000,000 private placement to support advancement into the Phase 3 RESCUE registrational program. The participation of prominent healthcare investors and the prospect of moving NDV-01 into late-stage trials highlight how clinical and financing...